Biohaven sinks as FDA declines to approve lead drug

Biohaven (BHVN) stock plunges as the FDA declines to approve its lead drug Vyglxia (troriluzole) targeted at spinocerebellar ...

Dynavax targets 60% U.S. hepatitis B market share by 2030 amid new COVID-19 vaccine deal and expanded share repurchase

Casale projected that HEPLISAV-B could reach at least 60% total market share in the U.S. by 2030, supported by expanding retail adoption and ongoing institutional demand.
StockStory.org on MSN

Herbalife (NYSE:HLF) Beats Q3 Sales Expectations, Stock Soars

Health and wellness products company Herbalife (NYSE:HLF) announced in Q3 CY2025, with sales up 2.7% year on year to $1.27 ...
TipRanks on MSN

Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Ventyx Biosciences (VTYX) to Buy from Neutral with an $18 price target The firm says the recent acquisition from Novartis ...